This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kyowa Hakko Kirin Co., Ltd.
Drug Names(s): toremifene citrate (60 mg)
Description: Fareston is also being developed for prostate cancer indications under the name Acapodene.
Fareston is a Selective Estrogen Receptor Agonist (SERM), and preferentially modulates (antagonist effect) estrogen beta receptors. Fareston inhibits estrogen-induced stimulation of DNA synthesis and cellular replication.
Roberts (Shire) and Orion
In September 1999, Roberts Pharmaceutical (Shire) acquired the US marketing rights for Fareston from Orion. In November 2004, Shire sold the US marketing rights for Fareston (toremifene) back to the license holder Orion.
Orion and GTx
In 2004, GTx signed an agreement with Orion to purchase all remaining rights to toremifene in the U.S. and additional rights in all other countries. At the time the partnership was established, Shire had already licensed from Orion the distribution rights in the U.S. to sell toremifene as Fareston for the treatment of metastatic breast cancer. Under the terms of the purchase agreement, GTx will pay approximately $5.2 million to Orion to acquire the existing U.S. Fareston business, including inventory and related license rights. GTx has no current or future financial obligations to Shire. GTx will continue to market Fareston in the U.S. for the treatment of metastatic breast cancer and will pay a...See full deal structure in Biomedtracker
Partners: Orion Corporation Eisai Co., Ltd.
Pink Sheet In Brief: Schering-Plough/Orion's Fareston
Pink Sheet Orion/Shire's Fareston (correction)
Pink Sheet In Brief: Schering/Orion's Fareston
Additional information available to subscribers only: